| Ident. | Authors (with country if any) | Title |
|---|
| 000015 (2021) |
Roberto Ariel Abelda O Zu Iga [Mexique] ; Silvia Mercedes Coca [Mexique] ; Giuliana Florencia Abelda O [Mexique] ; Ruth Ana María González-Villoria [Mexique] | Clinical effectiveness of drugs in hospitalized patients with COVID-19: a systematic review and meta-analysis. |
| 000016 (2021) |
Claudia Lilli ; Annibale Biggeri [Italie] ; Chiara Zingaretti ; Bernadette Vertogen ; Valeria Frassineti ; Roberto Vespignani ; Veruska Grossi ; Caterina Florescu ; Laura Matteucci ; Chiara Pazzi ; Alberto Bongiovanni ; Francesco Limarzi ; Valentina Fausti ; Lucia Bertoni ; Caterina Donati ; Francesca Galardi ; Nicola Gentili ; Francesco Mazza ; Giovanni Martinelli ; Oriana Nanni | Is it possible to conduct clinical trials during a pandemic? The example of a trial of hydroxychloroquine. |
| 000022 (2021) |
E. Díaz [Espagne] ; R. Amézaga Menéndez [Espagne] ; P. Vidal Cortés [Espagne] ; M G Escapa [Espagne] ; B. Suberviola [Espagne] ; A. Serrano Lázaro [Espagne] ; P. Marcos Neira [Espagne] ; M. Quintana Díaz [Espagne] ; M. Catalán González [Espagne] | [Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)]. |
| 000029 (2021) |
Maurizio Koch | [2020: Evidence-Based Medicine odyssey. The fall and rise of evidence-based medicine in the year of coronavirus.] |
| 000033 (2021) |
Dania Altulea [Pays-Bas] ; Sjors Maassen [Pays-Bas] ; Maksim V. Baranov [Pays-Bas] ; Geert Van Den Bogaart [Pays-Bas] | What makes (hydroxy)chloroquine ineffective against COVID-19: insights from cell biology. |
| 000037 (2021) |
Isabel Fambuena-Muedra [Espagne] ; Marta Jiménez-García [Belgique] ; Sarah Hershko [Belgique] ; Irene Altemir-G Mez [Espagne] ; Ana Tobarra-L Pez [Espagne] | What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects. |
| 000046 (2021) |
Paulo Roberto Bignardi [Brésil] ; Carolina Santos Vengrus [Brésil] ; Bruno Matos Aquino [Brésil] ; Alcindo Cerci Neto [Brésil] | Use of hydroxychloroquine and chloroquine in patients with COVID-19: a meta-analysis of randomized clinical trials. |
| 000049 (2021) |
Boghuma K. Titanji [États-Unis] ; Monica M. Farley [États-Unis] ; Ashish Mehta [États-Unis] ; Randi Connor-Schuler [États-Unis] ; Abeer Moanna [États-Unis] ; Sushma K. Cribbs [États-Unis] ; Jesse O'Shea [États-Unis] ; Kathryn Desilva [États-Unis] ; Bonnie Chan [États-Unis] ; Alex Edwards [États-Unis] ; Christina Gavegnano [États-Unis] ; Raymond F. Schinazi [États-Unis] ; Vincent C. Marconi [États-Unis] | Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019. |
| 000065 (2021) |
Guobing Li [République populaire de Chine, États-Unis] ; Shasha Ruan [République populaire de Chine] ; Xiaolu Zhao [République populaire de Chine] ; Qi Liu [États-Unis] ; Yali Dou [États-Unis] ; Fengbiao Mao [République populaire de Chine] | Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses. |
| 000077 (2021) |
Muhammad Sani Ismaila [Trinité-et-Tobago] ; Faruku Bande [Nigeria] ; Aminu Ishaka [Nigeria] ; Aminatu Abubakar Sani [Nigeria] ; Karla Georges [Trinité-et-Tobago] | Therapeutic options for COVID-19: a quick review. |
| 000084 (2021) |
Bhanu Prasad Venkatesulu [États-Unis] ; Viveksandeep Thoguluva Chandrasekar [États-Unis] ; Prashanth Giridhar [Inde] ; Pragathee V [Inde] ; Harsh K. Patel [États-Unis] ; Jacob Manteuffel [États-Unis] | The mechanistic rationale of drugs, primary endpoints, geographical distribution of clinical trials against severe acute respiratory syndrome-related coronavirus-2: A systematic review. |
| 000089 (2021) |
Kimberley Lewis [Canada] ; Dipayan Chaudhuri [Canada] ; Fayez Alshamsi [Émirats arabes unis] ; Laiya Carayannopoulos [Canada] ; Karin Dearness [Canada] ; Zain Chagla [Canada] ; Waleed Alhazzani [Canada] | The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials. |
| 000097 (2021) |
Jack Cook [États-Unis] ; Milton L. Pressler [États-Unis] ; Bharat Damle [États-Unis] ; Demissie Alemayehu [États-Unis] ; Charles A. Knirsch [États-Unis] | The Weight of Evidence From Electrophysiology, Observational, and Cardiovascular End Point Studies Demonstrates the Safety of Azithromycin. |
| 000099 (2021) |
Zelyn Lee [Canada] ; Craig R. Rayner [États-Unis, Australie] ; Jamie I. Forrest [Canada] ; Jean B. Nachega [Afrique du Sud, États-Unis, Canada] ; Esha Senchaudhuri [Canada] ; Edward J. Mills [Canada] | The Rise and Fall of Hydroxychloroquine for the Treatment and Prevention of COVID-19. |
| 000104 (2021) |
Farah Daou [Liban] ; Gretta Abou-Sleymane [Liban] ; Danielle A. Badro [Liban] ; Nagham Khanafer [France] ; Mansour Tobaiqy [Arabie saoudite] ; Achraf Al Faraj [Liban] | The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19. |
| 000105 (2021) |
Nour K. Younis [Liban] ; Rana O. Zareef [Liban] ; Mohammad Ali N. Maktabi [Liban] ; Rami Mahfouz [Liban] | The Era of the Coronavirus Disease 2019 Pandemic: A Review on Dynamics, Clinical Symptoms and Complications, Diagnosis, and Treatment. |
| 000107 (2021) |
O O Oleribe [Nigeria] ; P. Oskouipour [États-Unis] ; O. Nwanyanwu [États-Unis] ; S D Taylor-Robinson [Royaume-Uni] | The COVID-19 era: the view from Nigeria. |
| 000108 (2021) |
Masashi Ohe [Japon] ; Ken Furuya [Japon] ; Houman Goudarzi [Japon] | Tetracycline plus macrolide: A potential therapeutic regimen for COVID-19? |
| 000114 (2021) |
Viveksandeep Thoguluva Chandrasekar [États-Unis] ; Bhanuprasad Venkatesalu [États-Unis] ; Harsh K. Patel [États-Unis] ; Marco Spadaccini [Italie] ; Jacob Manteuffel [États-Unis] ; Mayur Ramesh [États-Unis] | Systematic review and meta-analysis of effectiveness of treatment options against SARS-CoV-2 infection. |
| 000137 (2021) |
Ça La Begüm Apayd N [Turquie] ; Gözde Ç Nar [Turquie] ; Gökçe Cihan-Üstünda [Turquie] | Small-molecule antiviral agents in ongoing clinical trials for COVID-19. |
| 000146 (2021) |
Rahul Sharma [Inde] ; Dharmendra Khokhar [Inde] ; Bhanushree Gupta [Inde] ; Purnendu Saxena [Inde] ; Kallol Kumar Ghosh [Inde] ; Arvind Kumar Geda [Inde] ; Kamil Kuca | Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2): A Review on Pathophysiology, Diagnosis and Investigational Therapeutics. |
